Introduction
Astrocytomas are the most common central nervous system neoplasm of childhood. 1 Although most pediatric low-grade astrocytomas (World Health Organization grades I and II) respond to surgery, radiation, and chemotherapy (overall survival, 70%-90%), high-grade astrocytomas (World Health Organization grades III and IV) remain resistant to current treatment regimens (overall survival, 25%-30%). [2] [3] [4] Thus, there is significant interest in identifying biologic markers that promote malignant progression and confer treatment resistance, and that in turn could be targeted for novel therapeutic intervention. There is substantial evidence that the malignant progression of astrocytomas in adults results in part from perturbation of growth factor receptor tyrosine kinase signaling pathways that promote cell proliferation, survival, migration, invasion, and other crucial functions characteristic of malignant cell behavior. [5] [6] [7] [8] [9] For example, progression from low-grade to high-grade astrocytoma in adults is characterized by amplification and overexpression of epidermal growth factor receptor (EGFR), and to a lesser degree, platelet-derived growth factor receptor (PDGFR). [10] [11] [12] Whether there are similar patterns of differential receptor tyrosine kinase expression in childhood astrocytomas is not known.
This distinction between adult and childhood astrocytomas is an important one, given that patterns of genetic alterations in high-grade astrocytomas that arise in the 2 populations appear to be different, despite the tumors having histologically identical appearances. For instance, TP53 mutations and EGFR amplification occur in approximately 50% of adult high-grade astrocytomas, but are much less frequently seen in pediatric high-grade astrocytomas. [13] [14] [15] These differences could have profound clinical implications for the translation of effective biologic target-driven therapeutics for high-grade astrocytomas in adults and children. Therefore, it is important to clearly define the unique genetic alterations that distinguish pediatric astrocytomas so the most appropriate therapeutic strategies may be designed.
In this study, we sought to identify the receptor tyrosine kinase and receptor tyrosine kinase-associated genes by monitoring their differential expression in low-grade and high-grade childhood astrocytomas, as a prerequisite for determining the best receptor tyrosine kinase candidates for future therapeutic targeting. To address this question, we first performed Affymetrix (Santa Clara, California) microarray gene profiling of primary untreated childhood non-brainstem astrocytomas to delineate the differentially expressed receptor tyrosine kinase-associated genes. We then selected the most differentially expressed receptor tyrosine kinase-associated genes for protein validation and in vitro functional testing as a way to gain further insight into the role of the identified receptor tyrosine kinase system in promoting the aggressive high-grade astrocytoma phenotype.
Materials and Methods

Tumor Specimens and Cells
Frozen tumor specimens were obtained from the Cooperative Human Tissue Network for the purpose of gene expression profiling, and paraffin-embedded tissue specimens were obtained from the pathology department of the Children's National Medical Center for the purpose of immunohistochemistry, with institutional review board approval. All samples were obtained from the primary tumor at the initial diagnostic biopsy and prior to any treatment. Specimens used for gene expression were immediately frozen in liquid nitrogen at the time of initial biopsy and then continuously stored at À80 C until used for array profiling. Frozen specimens consisted of 15 highgrade and 15 low-grade childhood astrocytomas. Specimens used for immunohistochemistry consisted of an independent set of 13 high-grade and 18 low-grade childhood astrocytomas. The astrocytoma cell lines T98, U87, U138, and CRL1718 were obtained from the American Type Culture Collection and grown at 5% CO 2 , 37 C in Minimal Essential Medium and 10% fetal calf serum.
Gene Expression Profiling
Microarray gene expression profiling was performed as described previously. 16, 17 In brief, total ribonucleic acid (RNA) was isolated from each snap-frozen astrocytoma and astrocytoma cell line using the TRIzol (Invitrogen, Carlsbad, California) reagent method. RNA was converted into double-stranded complementary DNA using the SuperScript Choice system (Invitrogen). The primer used for the first-strand complementary DNA synthesis was an oligo(dT)24 primer containing a T7 RNA polymerase promoter (Genset, San Diego, California). The doublestranded complementary DNA was purified by phenolchloroform extraction using Phase Lock Gel system. Cleaned complementary DNA was used for in vitro transcription using the ENZO Bioarray RNA transcript labeling kit (Affymetrix, Santa Clara, California). The biotin-labeled complementary RNA was then purified using the RNeasy kit (Qiagen, Valencia, California) and the complementary RNA was fragmented to approximately 200 bp by alkaline treatment (200 mM Tris-acetate, pH 8.2, 500 mM potassium acetate, 150 mM magnesium acetate). The integrity of each labeled complementary RNA was verified by hybridization to an Affymetrix TestChip2 array. Labeled complementary RNA was considered suitable if the ratio of the average intensity of the 3 0 to 5 0 ends of the b-actin gene is less than 3. Each verified complementary RNA was hybridized to the Affymetrix HU133A array (approximately 30 000 characterized fulllength gene sequences). Statistical analysis was performed using the Affymetrix software and permutation statistics, as described previously in detail. 16, 17 Immunohistochemistry Immunohistochemistry staining of the tumors was performed as described previously. 16, 17 In brief, 5-mm formalin-fixed paraffin-embedded tumor tissues were cut and immunohistochemistry was performed using the avidin-biotin complex method, with the DAKO Target Retrieval Solution (DakoCytomation, Carpinteria, California) used for antigen unmasking according to the manufacturer's protocol. Primary antibodies used were goat polyclonal antihuman insulin-like growth factor-binding protein 2 (IGFBP2; Santa Cruz Biotechnology, Santa Cruz, California), mouse monoclonal antihuman IGF-I (clone 1IGF01, NeoMarkers, Fremont, California), and goat polyclonal antihuman insulin-like growth factor-I receptor (IGF-IR; R&D Systems, Minneapolis, Minnesota) at 15 mg/mL. Secondary antibodies were diluted with 1.5% bovine serum albumin in phosphate-buffered saline as follows: 1:500 goat antimouse (Santa Cruz Biotechnology); and 1:300 rabbit antigoat (Santa Cruz Biotechnology). Section staining was photographed on a conventional light microscope at 200Â power. Normal brain tissue was used as background control. Two investigators (MRS and TJM) independently reviewed the specimens, and assigned a grading of the staining using a 0 to 4þ scoring as follows: 0, absent staining; 1þ, weak; 2þ, intermediate; 3þ, intermediate-strong; and 4þ, intense positive staining. Fisher exact test was used to determine significance of differential protein expression between high-grade and low-grade tumors based on the absence or presence of positive staining of any score between the 2 classes.
Migration Assay
Fibronectin-mediated cell migration was tested using the Chemicon QCM-FN Quantitative Cell Migration assay (Chemicon International, Temecula, California). Four astrocytoma cell lines, CRL1718, T98, U87MG, and U138, were tested. Cells were grown to 80% confluency and then starved in serum-free Minimal Essential Medium for 24 h prior to resuspension (1 Â 10 6 cells/mL) in serum-free Minimal Essential Medium with 5% bovine serum albumen for 1 h. Cells were washed to remove endogenous insulin-like growth factors (IGFs) and insulin-like growth factor-binding proteins (IGFBPs) and incubated at 37 C for 30 min with recombinant IGF-I (10 ng/mL, R&D Systems) or IGF-II (10 ng/mL, R&D Systems), with or without recombinant insulin-like growth factor-binding protein 2 (IGFBP2) (5-50 ng/mL, R&D Systems). Untreated cells were used as the baseline controls. After incubation, cells were washed and resuspended in aliquots of 2 Â 10 5 cells in 200 mL of serum-free Minimal Essential Medium and plated into the upper fibronectin-coated or bovine serum albumen-coated (negative control) Boyden chambers. The lower chambers contained 300 mL of serum-free Minimal Essential Medium with insulin-like growth factor-binding protein 2 (100 ng/mL) to establish a chemotactic gradient. The cells were incubated for 3 h at 37 C and then cells on the upper side of the membrane were removed with a cotton swab and cells migrating to the lower side of the membrane were fixed and stained with Diff-Quick solution kit (Chemicon). Stained migrating cells were eluted with an extracting solution according to manufacturer's instructions (Chemicon). Two 50 mL aliquots of eluant were placed into a microtiter-plate well and optical density was measured using a Thermomax microplate reader (Molecular Devices) at 550 nm. Using a standardized migration rate of 130 cells/mm 2 , equivalent to an optical density at 550 nm of 0.270 (per Chemicon protocol), we obtained the final cell counts by averaging the 2 optical density measurements after subtraction of the bovine serum albumen negative control measurements (background). Assays were repeated twice. Statistical significance was calculated using a Student t test.
Microarray Analysis of IGFBP2-Stimulated Astrocytoma Cells
T98 and U87 cells (1 Â 10 6 ) were grown to 70% confluency in T75 flasks and then starved in serum-free Minimal Essential Medium overnight. Cells were then stimulated with insulin-like growth factor-binding protein 2 (50 ng/mL), insulin-like growth factor-I (IGF-I) (10 ng/mL), or negative control serum-free Minimal Essential Medium for 24 h and incubated in 5% CO 2 at 37 C. The cells from each flask were then collected and frozen at 4 time points: 0, 1, 8, and 24 h poststimulation. All cells were frozen in phosphate-buffered saline at À80 C until used for gene profiling. Expression profiling of stimulated astrocytoma cells was performed as described above using the HU133A Affymetrix array. The assay was repeated 3 separate times and the Affymetrix software was used to perform the statistical analysis.
Western Blot of IGFBP-Stimulated Astrocytoma Cells
T98 and U87 cells (1 Â 10 6 ) were grown to 70% confluency in T75 flasks and then starved in serum-free Minimal Essential Medium overnight. Cells were then stimulated with insulin-like growth factor-binding protein 2 (5-50 ng/mL), IGF-I (1-10 ng/mL), or negative control serum-free Minimal Essential Medium for 24 h and cells from each flask were collected in lysis buffer at 4 time points: 24, 48, 72, and 96 h poststimulation for subsequent Western blot analysis. In brief, whole cell lysate protein concentrations were determined using Bradford dye-binding assay (Bio-Rad, Grand Prairie, Texas). Approximately, 15 mg of protein was equally loaded on 7.5% or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Membranes were incubated with 0.5 mg/mL rabbit polyclonal anti-human DNA-PKcs antibody (Oncogene Research Products, Cambridge, Massachusetts) overnight at 4 C, washed, and then secondary antibody was added using goat anti-rabbit immunoglobulin G horseradish peroxidase (HRP)-linked (Cell Signaling Technology, Beverly, Massachusetts) diluted 1:3000 (3 mL in 10 mL of blocking buffer) and incubated for 1 h at room temperature. Blots were incubated in LumiGLO (Cell Signaling Technology) reagent for 5 min, and then exposed. Protein signal strengths were quantitated by densitometric analysis using software from Scion Corporation (Frederick, Maryland) and then values were converted to the relative ratio of DNA-PKcs:actin. The assay was performed 3 separate times. Statistical significance was calculated using a Student t test.
Results
Gene Expression Profiling of Childhood Astrocytomas
To determine differential expression of specific receptor tyrosine kinase and receptor tyrosine kinase-associated genes in pediatric low-grade and high-grade astrocytomas, we performed Affymetrix microarray gene expression profiling (approximately 30 000 gene sequences) of 30 primary non-brain stem astrocytomas (15 high-grade, 15 low-grade) obtained at the time of diagnosis and prior to treatment. Genes were ranked according to P value and the top 50 differentially expressed genes were screened for the presence of known receptor tyrosine kinase or receptor tyrosine kinase-associated genes. In order of increasing P value, 3 receptor tyrosine kinase/receptor tyrosine kinase-associated genes were significantly upregulated in high-grade astrocytomas compared with low-grade astrocytomas: (1) IGFBP2, (2) EGFR, and (3) ephrin receptor B4 (EPHB4); and 6 receptor tyrosine kinase/receptor tyrosine kinase-associated genes were significantly downregulated in high-grade astrocytomas compared with low-grade astrocytomas: (1) IGF-I, (2) fibroblast growth factor 1 (FGF1), (3) fibroblast growth factor 2 (FGF2), (4) granulocyte-monocyte colony-stimulating factor receptor (GMCSFR), (5) brain-derived neurotrophic factor receptor (tyrosine receptor kinase B, TRKB), and (6) granulocyte colony-stimulating factor receptor (GCSFR). The results of the statistically significant differentially expressed receptor tyrosine kinase and receptor tyrosine kinase-associated genes, defined as genes with threshold P < .01, are summarized in Table 1 .
Validation of IGFBP2 Protein Overexpression by High-Grade Astrocytomas
Insulin-like growth factor-binding protein 2 was selected for protein validation and further investigation because of its highly significant differential messenger RNA overexpression (P ¼ .0006). An independent set of 31 paraffinembedded astrocytomas was used for IGFBP2 protein expression validation by immunohistochemistry. Nine of 13 (69%) high-grade astrocytomas had positive staining, whereas only 5 of 18 (28%) low-grade astrocytomas had positive staining (P ¼ .027, Fisher exact test). Insulin-like growth factor-binding protein 2 protein expression was detected diffusely in high-grade tumor cells throughout the tumor sections and intense staining was noted in focal clusters of cells within sections. Positive staining did not appear to be associated with areas of necrosis, vascularity, or high cell density. Although some low-grade tumors had detectable diffuse IGFBP2 expression, intense staining of IGFBP2 in focal clusters of cells was only observed in high-grade tumors (Figure 1 ). Insulin-like growth factor-I protein expression was relatively decreased in high-grade tumors, while IGF-IR protein was similarly expressed between the tumor classes (results not shown), consistent with the microarray data results. Insulin-like growth factorbinding protein 2 protein was not detected in normal brain. Table 2 summarizes the immunohistochemistry results. Abbreviations: EGFR, epidermal growth factor receptor; EPHB4, ephrin receptor B4; FGF1, fibroblast growth factor 1; FGF2, fibroblast growth factor 2; GCSFR, granulocyte colony-stimulating factor receptor; GMCSFR, granulocyte macrophage colony-stimulating factor receptor; HGA, high-grade astrocytoma; IGF-I, insulin-like growth factor I; IGFBP2, insulin-like growth factor-binding protein 2; TRKB, tyrosine receptor kinase B. a Significance in differential gene expression between tumor classes was determined using permutational t test statistics. 
Effect of IGFBP2 Stimulation on Astrocytoma Cell Migration
The IGF system has been reported to influence tumor cell migration and astrocytoma invasion. [18] [19] [20] [21] To determine whether IGFBP2 directly modulates the migration of astrocytoma cells, we tested 4 astrocytoma cell lines stimulated with IGF-I or IGF-II (both 10 ng/mL), with or without IGFBP2 (50 ng/mL) treatment, and compared the migration rates obtained after stimulation using an in vitro fibronectin-coated Boyden chamber migration assay. Fibronectin coating was used because of previous reports suggesting that IGF facilitates cell migration on fibronectin through interaction with the fibronectin-binding integrins. [22] [23] [24] Incubation with increasing concentrations of IGFBP2 alone (5-50 ng/mL) did not affect the migration of astrocytoma cells on fibronectin compared with baseline untreated control cells (data not shown). Compared with controls, IGF-I and IGF-II modestly increased cell migration in a consistent fashion in all 4 cell lines tested, whereas IGFBP2 only minimally inhibited IGF-I-mediated migration of astrocytoma cells (Figure 2 ). Insulinlike growth factor-binding protein 2 had no effect on IGF-II-mediated migration. Insulin-like growth factorbinding protein 2 stimulation, with or without IGF-I or IGF-II, also had no effect on the growth of any of the cells tested, as measured by cell counts, under the same conditions (data not shown). 
IGFBP2 Stimulation Induces Astrocytoma DNA-PK Gene Expression
To elucidate whether IGFBP2 plays a functional role in modulating astrocytoma gene expression that may promote the high-grade phenotype independent of the IGF system, we performed serial microarray gene expression profiling, using the Affymetrix U133 array (approximately 30 000 characterized gene sequences), of serum-depleted T98 and U87 cells stimulated with IGFBP2, IGF-I, or Minimal Essential Medium alone (negative baseline control). At 1 h, only 1 transcript, DNA-dependent protein kinase catalytic subunit (DNA-PKcs), was consistently upregulated by stimulation with IGFBP2 but not affected by IGF-I, compared with the Minimal Essential Mediumstimulated baseline negative control cells in all 3 separate experiments and in both cells. On the basis of this unexpected finding, we reanalyzed the initial tumor profiling results and noted that DNA-PKcs was also significantly upregulated in high-grade astrocytomas in comparison with low-grade astrocytomas (P ¼ .0008; Table 3 ). Only 1 gene, protein tyrosine kinase 9 (PTK9), was differentially downregulated at 1 h after IGFBP2 stimulation of both cells; however, PTK9 was not found differentially expressed by the tumors. At all other time points tested, no other oncogenic kinases were consistently differentially expressed in comparison with baseline control cells in an IGF-independent manner in both cells.
IGFBP2 Stimulation Induces Astrocytoma DNA-PK Protein Expression
To validate that IGFBP2 stimulation induces astrocytoma cell DNA-PKcs expression independent of the IGF system, we stimulated T98 cells with increasing concentrations of IGFBP2 and over different time points and compared DNA-PKcs expression, as measured by Western blot of whole cell lysates, with that of cells stimulated with IGF-I. Insulin-like growth factor-binding protein 2 stimulation induced protein expression of DNA-PKcs in both a dose-dependent and time-dependent manner, while IGF-I had no significant effect on the protein expression of DNA-PKcs (Figure 3) . Similar results were observed in U87 cells (not shown).
Discussion
We show for the first time that IGFBP2 and DNA-PKcs are highly overexpressed by high-grade childhood astrocytomas at the protein and transcriptional level, respectively. Moreover, in comparison to all other receptor tyrosine kinase or receptor tyrosine kinase-associated genes screened, we identified IGFBP2 as most overexpressed in high-grade astrocytomas, followed by EGFR and EPHB4. In fact, these 3 genes were the only receptor tyrosine kinase-associated genes differentially overexpressed with P < .01, thereby implicating IGFBP2, EGFR, and EPHB4 as the major receptor tyrosine kinase-associated genes characterizing the malignant phenotype of childhood astrocytoma. Finally, we show that IGFBP2 directly induces DNA-PKcs messenger RNA and protein expression in a dose-dependent and time-dependent manner, independent of IGF, thus demonstrating a novel function for IGFBP2 in astrocytoma cells that could have important clinical implications. High-grade pediatric astrocytomas overexpress EGFR, a potent mitogenic receptor. 13 Our results confirm this finding and also show that EGFR is significantly differentially expressed. Expression of the ephrin receptor, EPHB4, which has not been shown before in childhood astrocytomas, is an important regulator of angiogenesis. 25 Elevated concentrations of IGFBP2 have been reported in the cerebrospinal fluid of children with high-grade brain tumors compared with peripheral tumors. 26 We previously demonstrated, in a separate cohort of pediatric astrocytomas, the overexpression of IGFBP2 in high-grade astrocytomas in an analysis that was restricted to 133 angiogenesisassociated genes. 16 Surprisingly, our analysis of approximatley 30 000 genes in this larger cohort of pediatric astrocytomas showed that IGFBP2 maintained its significance as the most discriminating gene for malignant astrocytoma among receptor tyrosine kinase-associated genes. In adult glioblastoma, IGFBP2 is similarly overexpressed and expression correlates directly with tumor grade. 27, 28 In diffuse astrocytomas in adults, IGFBP2 was the most distinct progression-related change found, correlating with progression and poor patient survival. 29 Another study similarly reported that IGFBP2 discriminated primary from nonprimary glioblastoma in adults and that IGFBP2 was coexpressed with vascular endothelial growth factor (VEGF) in areas of tumor necrosis. 30 More recently, a significant positive correlation was demonstrated between expression of IGFBP2-matrix metalloproteinase-2 (MMP2) and IGFBP2-VEGF in adult glioblastoma, but not anaplastic astrocytoma. 31 Together, these findings suggest a potential important role for IGFBP2 in astrocytoma invasion and angiogenesis.
The IGF system, composed of 2 peptide ligands (IGF-I and IGF-II), 6 high-affinity IGF-binding proteins (IGFBP1-IGFBP6), and 2 IGF receptors (IGF-IR and IGF-IIR), has mitogenic and antiapoptotic effects on malignant cells. 32 IGF-I and IGF-II appear to exert their mitogenic signaling through IGF-IR. 32 IGFBPs tightly regulate the biological actions of IGFs by sequestering IGFs away from their receptors and targeting for degradation. 32 Overexpression of IGF-I, IGF-II, and their respective receptors has been shown in adult astrocytomas, and expression correlates with histologic grade. 33, 34 In contrast, our study did not find differential expression of IGF-II, IGF-IR, or IGF-IIR, indicating that the biology of the IGF system in astrocytomas in children may be distinct from that in adults. Moreover, we show that IGF-I is downregulated in high-grade astrocytomas, suggesting that the regulation of IGFBP2 expression, and consequently its function, is independent of the IGF system in these tumors. This differs from normal neurodevelopment, whereby IGF-I and IGFBP2 expression is temporally synchronized, peaking together during postnatal glia maturation. 35 Thus, it appears that the IGF system is dysregulated in childhood malignant astrocytomas. Because of our data demonstrating overexpression of IGFBP2 on the messenger RNA and protein level, we explored the possibility of IGF-independent functions for IGFBP2 in promoting the aggressive behavior of malignant astrocytomas.
Although accumulating evidence demonstrates that IGFBP2 is also overexpressed in noncentral nervous system malignancies, 36, 37 its functional role in tumor progression remains unclear. Glioblastoma cells stably transfected with IGFBP2 demonstrated enhanced invasion and activation of invasion-promoting genes such as MMP2. 20 However, in vascular smooth muscle cells, exogenous IGFBP2 inhibited IGF-I-stimulated migration and DNA synthesis. 38 A more recent report showed that integrin avb3 and IGFBP2 act cooperatively to reduce breast cancer cell migration. 39 In contrast to these reports, we found no direct effect of IGFBP2 stimulation alone on astrocytoma cell migration and only minimal inhibition of IGF-I-mediated (but not IGF-II-mediated) migration on fibronectin. Moreover, our data of astrocytoma cells exposed to IGFBP2 did not support a role for IGFBP2mediated gene expression promoting growth, invasion, or migration.
Evidence suggests that IGFBP2 may have IGFindependent effects. 32 In support of this, we show for the first time that messenger RNA and protein expression of DNA-PKcs is induced by IGFBP2 stimulation of astrocytoma cells, yet is unaffected by IGF-I stimulation. DNA-PKcs is a nuclear serine/threonine kinase that plays a crucial role in repairing double-strand breaks secondary to radiation-induced and chemotherapy-induced damage, and overexpression of DNA-PKcs activity in tumor cells confers resistance to killing by ionizing radiation. [40] [41] [42] Interestingly, a recent report demonstrated that blockade of radiation-induced import of EGFR to the nucleus abolished DNA-PK activation, suggesting that EGFR expression may also be crucial to DNA-PK repair function. 43 DNA-PK also controls c-myc and MAGE-A gene transcription and phosphorylates key proteins regulating cell cycle and apoptosis, including p53, transcription factor Sp1, myc, replication protein A, and RNA polymerase I. [44] [45] [46] Our data confirm that DNA-PKcs is differentially overexpressed in high-grade tumors. Expression of IGFBP2 is regulated by the hypoxia-inducible transcription factors, HIF-1a and HIF-2a. 32 We have previously shown that HIF-2a is also significantly upregulated in high-grade childhood astrocytomas. 16 Because hypoxic tumor areas are relatively radiation resistant, we speculate that 1-way high-grade astrocytomas may acquire radiation resistance is through HIF-mediated IGFBP2 expression, which in turn promotes DNA-PKcs expression that is activated by EGFR nuclear import.
In summary, we conclude that IGFBP2 is highly differentially overexpressed by malignant childhood astrocytomas and that a novel function of IGFBP2, independent of the IGF system, is to induce DNA-PKcs expression. Thus, together with EGFR-mediated activation of DNA-PKcs, IGFBP2 may serve to protect astrocytomas from therapeutic killing, thereby contributing to the overall malignant potential of these cells. Further studies are needed to confirm these mechanistic associations and to delineate how IGFBP2 upregulates DNA-PKcs. Ultimately, these studies may help define IGFBP2 as a novel target for therapeutic intervention in high-grade childhood astrocytomas.
